5:46 PM
 | 
Oct 28, 2013
 |  BC Extra  |  Clinical News

Polaris' ADI-PEG 20 meets in Phase II mesothelioma trial

Polaris Pharmaceuticals Inc. (San Diego, Calif.) said once-weekly intramuscular ADI-PEG 20 plus best supportive care (BSC) for six months met the primary endpoint of improving median...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >